Related Experiment Videos
The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study
K P Hayhurst1, P Brown, S W Lewis
1School of Psychiatry and Behavioural Sciences, University of Manchester, Wythenshawe Hospital, UK. khayhurst@fs1.with.man.ac.uk
Journal of Psychopharmacology (Oxford, England)
|July 4, 2002
Summary
Clozapine significantly reduces hospital admissions and costs for severe schizophrenia patients. This antipsychotic medication offers both clinical and economic benefits in real-world settings.
Area of Science:
- Psychiatry and Mental Health
- Pharmacoeconomics
- Health Services Research
Background:
- Severe schizophrenia often involves high inpatient service utilization.
- Clozapine is an effective treatment but its real-world cost-effectiveness requires evaluation.
Purpose of the Study:
- To assess the impact of clozapine initiation on inpatient service utilization and associated costs.
- To compare outcomes in patients continuing versus discontinuing clozapine treatment.
Main Methods:
- Retrospective cohort study with a mirror-image design.
- Inclusion of 63 patients initiated on clozapine, compared to a matched control group.
- Intent-to-treat analysis including patients who discontinued clozapine.
Main Results:
- Significant reduction in hospital admissions and duration of stay in the 2 years post-clozapine initiation.
- Average reduction of £7,300 in hospitalization costs per patient over 2 years.
- Patients continuing clozapine showed a two-thirds reduction in admissions and hospital time.
Conclusions:
- Clozapine is a clinically effective intervention for severe schizophrenia in routine practice.
- Clozapine demonstrates significant cost-effectiveness by reducing inpatient service utilization.